Drugs / JNJ-95804306
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07572006 | May 2026 → May 2029 expected | hematopoietic and lymphoid cell neoplasm | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-95804306 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07572006 ↗ |
| Route | Oral | “administered orally” NCT07572006 ↗ |